Pleading Disability Discrimination Under ACA § 1557 for Obesity-Related Coverage Exclusions Requires “Fit” and “Meaningful Access” Facts

1. Introduction

Parties. Plaintiff-Appellant Rebecca Holland, a public school employee enrolled in a Maine Education Association Benefits Trust health plan, sued Defendant-Appellee Elevance Health, Inc. (parent of Anthem Health Plans of Maine, Inc., the plan’s designer/administrator).

Background. The plan contained an exclusion stating that “[b]enefits are not provided for weight loss medications.” After being diagnosed with obesity and prescribed FDA-approved medications (Wegovy and Contrave), Holland was repeatedly denied coverage. Her providers appealed and submitted additional documentation; coverage remained unavailable because her plan “did not cover Wegovy.”

Claim and key issue. Holland brought a putative class action under ACA § 1557, asserting that the plan’s weight-loss medication exclusion discriminated against enrollees diagnosed with obesity—allegedly a disability—through intentional discrimination, proxy discrimination, and disparate impact. The decisive appellate question became whether Holland plausibly alleged that she (and the class) were denied plan benefits “solely by reason of” disability as required by Rehabilitation Act § 504 principles incorporated into § 1557.

2. Summary of the Opinion

The First Circuit affirmed dismissal under Rule 12(b)(6). Applying Rehabilitation Act § 504 standards to ACA § 1557 claims, the court held that Holland failed to plausibly plead the “solely by reason of” element.

• Proxy discrimination: Even assuming such a theory is viable, the complaint did not plead facts showing a sufficiently close “fit” between the exclusion (weight-loss medications) and the allegedly disabled group (people with “disabling obesity”).
• Intentional discrimination: The exclusion was facially neutral because it applied to any enrollee seeking weight-loss drugs, not only those with obesity; and the deliberate-indifference allegations did not plausibly show knowledge of a substantial likelihood of violating federally protected rights.
• Disparate impact: Holland did not plausibly allege denial of “meaningful access” to a benefit “that the grantee offers,” because she did not articulate the scope of the relevant “prescription drug benefit” that the ACA guarantees in this context.

3. Analysis

3.1 Precedents Cited

A. Pleading and Rule 12(b)(6) framework

• Freeman v. Town of Hudson and San Juan Cable, LLC v. P.R. Tel. Co.: Used for the standard move at dismissal—accepting well-pleaded facts and drawing reasonable inferences for the plaintiff. The court signaled that the shortcoming here was not a failure to credit facts, but the absence of facts supporting discrimination inferences.
• Rae v. Woburn Pub. Schs. and Fantini v. Salem State Coll.: Reinforced de novo review and the “well-pleaded facts” requirement, framing why conclusory allegations about disability-discrimination mechanisms do not survive.
• Frith v. Whole Foods Mkt., Inc.: Provided the “conceivable to plausible” line; the court relied on it to reject conjectural claims about who is affected by the exclusion and whether effects concentrate on disabled individuals.
• Waleyko v. Phelan: Cited to underscore that “unsubstantiated conclusions” are not credited—important because Holland attempted to minimize the exclusion’s reach to non-disabled enrollees through unsupported assertions.
• United States v. Zannino: Used to deem waived a new appellate argument about “medical necessity” language in the plan (i.e., an attempt to argue overweight individuals could not obtain coverage even absent the exclusion).
• Saccoccia v. United States and Butler v. Balolia: Supported the court’s ability to consider documents incorporated by reference and public records—allowing it to consult the FDA materials linked in the complaint to test plausibility of the claimed “fit.”

B. Section 1557 and Rehabilitation Act § 504 elements

• Schmitt v. Kaiser Found. Health Plan of Wash.: Served two roles. First, it supplied the analytic bridge that Rehabilitation Act case law governs ACA § 1557 disability claims against health insurers. Second, it provided the key “proxy discrimination” inquiry—whether a proxy’s “fit” is sufficiently close to support a discrimination inference.
• Lesley v. Hee Man Chie: Provided the First Circuit’s four-element framework for § 504 claims, including the contested requirement that denial be “solely by reason of” disability—the element on which Holland’s case failed.

C. Proxy discrimination authorities (and why Holland’s proxy theory failed)

• Pac. Shores Props., LLC v. City of Newport Beach: Furnished a definition of proxy discrimination: ostensibly neutral criteria so closely associated with a disfavored group that they function as constructive facial discrimination. The opinion also used McWright v. Alexander (gray hair as proxy for age) as the classic “fit” example.
• Davis v. Guam: Cited through Schmitt for the “fit” framing.
• Schmitt v. Kaiser Found. Health Plan of Wash.: The court drew heavily on Schmitt’s rejection of proxy allegations where over-inclusiveness could not be plausibly assessed. Holland’s complaint, like the plaintiffs’ in Schmitt, did not quantify or concretely describe the affected population so a court could infer that disabled individuals were the primary burden-bearers.

D. Intentional discrimination and deliberate indifference

• Lovell v. Chandler: Provided the two-part deliberate indifference test (knowledge of substantial likelihood of harm to a federally protected right; failure to act).
• Basta v. Novant Health Inc., Updike v. Multnomah Cnty., and Duvall v. Cnty. of Kitsap: Used to stress that deliberate indifference requires more than negligence; the court treated Holland’s “thoughtless indifference or benign neglect” theory as insufficiently culpable even if deliberate indifference were cognizable in this context.
• Cook v. State of R.I., Dep't of Mental Health, Retardation, & Hosps.: Holland invoked it for the proposition that obesity can be a federally protected disability. The panel did not adopt a broad rule about obesity, instead concluding that—even assuming obesity could qualify—Holland still did not plausibly plead that Elevance knew the challenged exclusion was substantially likely to violate § 1557 rights.

E. Disparate impact and “meaningful access”

• Alexander v. Choate: The controlling conceptual anchor. The court used it to reject “boundless” disparate-impact liability under § 504 and to apply the “meaningful access to the benefit that the grantee offers” limitation. Holland failed, in the court’s view, to define the relevant benefit’s scope under the ACA in a way that made “meaningful access” denial plausible.

3.2 Legal Reasoning

A. The “solely by reason of” disability bottleneck

The court treated the case as turning on the fourth § 504 element: whether Holland was denied services “solely by reason of” disability. The panel emphasized that even if disability were plausibly alleged (the district court assumed so for the motion), the complaint still had to connect the exclusion to disability-based causation rather than to a plan design choice applicable to disabled and non-disabled enrollees alike.

B. Proxy discrimination: “fit” requires facts about who is affected and why

The court assumed, arguendo, that proxy discrimination might be cognizable and asked whether weight-loss medication exclusion “fit” obesity disability closely enough to infer discrimination. It concluded the complaint did not supply such facts.

Critically, the court used the FDA materials (linked by Holland) to show the opposite: drugs like Wegovy and Zepbound are approved for some individuals who are overweight with weight-related conditions. That approval undermined the asserted one-to-one relationship between the proxy (weight-loss drugs) and the protected status (disability).

The court also rejected Holland’s attempt to plead away over-inclusiveness (i.e., to claim that non-disabled “weight control” seekers are not meaningfully affected) because the allegations lacked concrete factual support and amounted to conjecture.

C. Intentional discrimination: facial neutrality and insufficient scienter for deliberate indifference

Facial discrimination. Holland argued the plan’s placement of the exclusion under “Bariatric Surgery / Morbid Obesity” demonstrated express targeting of obesity. The court disagreed because the exclusion was also stated as a general pharmacy-benefit carveout (“[a]ny [d]rug mainly used for weight loss” is not covered), which, as written, applies to all enrollees regardless of diagnosis.

Deliberate indifference. Even if deliberate indifference could establish intentional discrimination in this setting (an issue the court did not decide), Holland’s allegations did not plausibly show the required knowledge that violating federally protected rights was “substantially likely.” Allegations that Elevance did not run certain analyses (cost-benefit, evidence review, legal compliance review) were treated as, at most, negligence—not the deliberateness the cited cases require.

D. Disparate impact: “meaningful access” depends on a defined benefit baseline

Holland’s disparate-impact theory framed the prescription drug benefit as something to which enrollees with obesity lacked “meaningful access.” The court, invoking Alexander v. Choate, required a more precise identification of “the benefit that the grantee offers” and the scope of that benefit under the governing statute.

The court concluded Holland did not allege facts permitting an inference that the ACA requires plan designs to cover “every form of medically necessary treatment for a disabled individual's particular condition.” Without that baseline, the complaint did not plausibly state that the exclusion denied meaningful access to the offered benefit (as opposed to reflecting a permissible coverage limitation applied neutrally).

3.3 Impact

Practical litigation consequences. The decision will likely shift § 1557 benefit-design litigation toward more developed, data-supported pleadings (or pre-suit investigation) describing affected populations, prescribing criteria, and comparative access. It also signals skepticism toward reframing neutral “category of drug” exclusions as disability discrimination without a tight causal chain.

4. Complex Concepts Simplified

• ACA § 1557 (42 U.S.C. § 18116): A broad healthcare nondiscrimination provision. For disability claims, it incorporates Rehabilitation Act § 504 standards and remedies.
• Rehabilitation Act § 504 (29 U.S.C. § 794): Prohibits disability discrimination by entities receiving federal financial assistance. In many formulations, liability requires that the adverse action occur “solely by reason of” disability.
• ADA “disability” definition: Typically an impairment that “substantially limits” one or more “major life activities.” The court did not finally decide whether obesity here met that definition; the case failed on causation and plausibility of discrimination mechanisms.
• Proxy discrimination: Using a seemingly neutral criterion that is so closely associated with a protected group that it effectively functions as discrimination against that group. The key is how close the “fit” is.
• Over-inclusiveness (“overdiscrimination”): A proxy may sweep in some non-protected people. That does not automatically defeat a proxy claim, but plaintiffs must plead facts showing the proxy still primarily targets (or disproportionately burdens) the protected group.
• Facial discrimination: A policy explicitly classifies people based on a protected trait. The court found this exclusion facially neutral because it applied to anyone seeking weight-loss drugs, not expressly to disabled persons.
• Deliberate indifference: More than carelessness. It generally requires knowledge that violating a federally protected right is substantially likely and then choosing not to act.
• Disparate impact / “meaningful access”: Even if a neutral policy burdens disabled people more, § 504 (per Alexander v. Choate) typically requires showing that disabled people lack meaningful access to the specific benefit the program offers—not that outcomes are equal or that every helpful service is covered.

5. Conclusion

Holland v. Elevance Health, Inc. reinforces pleading discipline for ACA § 1557 disability challenges to health-plan benefit design. The First Circuit required factual allegations that connect an exclusion to disability-based causation—either by demonstrating a sufficiently close proxy “fit,” showing intentional discrimination on the face of the plan or through properly pled deliberate indifference, or establishing a Choate-style denial of “meaningful access” to a defined offered benefit. Absent those facts, a weight-loss medication exclusion—however consequential to individuals with obesity—will not plausibly state a § 1557 disability discrimination claim in this Circuit.